Abnormalities of immune surveillance may contribute to the development of myeloid malignancy as well as immune-mediated diseases. In leukaemia, allogeneic haemopoietic stem cell transplantation (alloHSCT) has been used to induce disease remission, in part by restoring mechanisms of immune regulation. Although, by the same principle, allogeneic stem cell transplantation is an attractive option for the treatment of immunological disorders, it is unclear whether remission after transplantation is due to pre-transplant conditioning, or modulation of auto-reactive lymphocytes by cells in the allograft. We report the case of a patient with chronic myeloid leukaemia (CML) who received an allogeneic bone marrow transplant (alloBMT) from his brother. He subsequently suffered a cytogenetic and molecular relapse of CML. At the same time, sarcoidosis involving the marrow was diagnosed. He was treated with donor lymphocyte infusions (DLI) and attained remission from CML; in addition, no giant cell granulomas were detected in the marrow, indicating resolution of sarcoidosis. This case illustrates the need for further studies on the role of T cell-based therapies in the management of immune-mediated disorders. Bone Marrow Transplantation (2001) 27, 757-759. 
Dysregulation of immune surveillance may contribute to myeloid malignancy by permitting development of an abnormal clone of haemopoietic progenitor cells. 1 After alloBMT, suppression of leukaemic clones by donor T lymphocytes within the allograft is thought to result in sustained remission. 2 This graft-versus-leukaemia (GVL) effect is also evident in the ability of DLI to restore donor haemopoiesis in CML with molecular relapse after alloBMT. 3 Abnormalities of immune regulation are also a feature of autoimmune and immune-mediated disorders, and result in the inappropriate survival of auto-reactive lymphocytes. 4 Immunosuppressive therapy with drugs has been the mainstay of treatment of most of these diseases; more recently, a role for allogeneic stem cell transplantation in treating refractory disease has been identified. Based on the evidence from alloBMT in leukaemia, it has been suggested that a graft-versus-autoimmune (GVA) effect similar to GVL could be induced after alloHSCT in autoimmune disease and may potentially suppress the auto-reactive clone. 5 This concept is supported by reports of long-term remission in some patients with autoimmune disease transplanted for co-existing haematological disorders. [6] [7] [8] We report a patient who developed marrow sarcoidosis along with cytogenetic and molecular relapse of CML after a matched sibling BMT for CML. Following treatment with DLI, he re-entered remission: furthermore, there was no evidence of granulomas in the marrow, indicating resolution of sarcoidosis. This case thus adds to the existing evidence favoring a role for T cell-based immunotherapy in treating immune-mediated diseases.
Case history
A 36-year-old man presented with hepatosplenomegaly, anaemia and an elevated white cell count (486 × 10 9 /l). Peripheral blood and marrow features and immunophenotyping were consistent with chronic phase CML. The Philadelphia (Ph) chromosome [t(9;22) (q34;q11)] was detected in marrow cells confirming the diagnosis. A constitutional pericentric inversion of chromosome 9 (p11q13) was also present on the derivative chromosome. Following leukopheresis, the patient was commenced on hydroxyurea to control the white cell count. Of the patient's five siblings, his 32-year-old brother was HLA-compatible [A-24(9) B-8 52(5) C-7 16; DR-17(3) 18(3) DQ-2 4 DP-] and a suitable donor for an alloBMT. Neither donor nor recipient had evidence of previous infection with cytomegalovirus. Although the donor was under investigation for granulomatous hepatitis, this was not thought to be a contra-indication to a marrow transplant.
An alloBMT using in excess of 3 × 10 8 donor cells/kg was performed 7 months after the initial diagnosis. The pretransplant conditioning regimen consisted of fractionated total body irradiation 1440 cGy and cyclophosphamide (120 mg/kg). Cyclosporin A and short-course methotrexate were used to prevent graft-versus-host disease (GVHD).
Standard prophylactic doses of ciprofloxacin, acyclovir and fluconazole were used against bacterial, viral and fungal infections, respectively.
The immediate post-transplant period was uncomplicated and neutrophil engraftment (Ͼ0.5 × 10 9 /l) was achieved on day +14. There was no convincing evidence of GVHD. The patient was discharged from hospital on day +23. Bone marrow examination at 4 weeks and 3 months post transplantation showed normal (Ph−) male karyotype with no evidence of inv (9) . Furthermore, molecular analysis of marrow DNA did not detect bcr-abl, confirming complete remission.
Twenty-one months post transplantation, cytogenetic analysis of bone marrow identified the Ph chromosome along with inv(9) in a minority of cells (2/23). Fluorescence in situ hybridisation (FISH) studies and RT-PCR analysis of marrow detected bcr-abl in up to 2.5% of cells. In trephine sections, multinucleate giant cell granulomas without caseation necrosis were seen, along with an increase in surrounding reticulin (see Figure 1) . No acid-fast bacilli or fungi were detected within the granuloma. It then became evident that the patient had a family history of sarcoidosis: one brother aged 39 had died of the disease and the other, the marrow donor, suffered from sarcoidosis of the liver. Serum angiotensin converting enzyme (ACE) levels in the patient were therefore measured and these were mildly elevated at 73 (normal range 10-54 IU/l). CT scan of the thorax was unremarkable. Thus, along with possible relapse of CML, the patient had developed marrow sarcoidosis.
Molecular analysis of marrow after 2 weeks indicated the presence of bcr-abl once again, and quantitative PCR detected 6 × 10 4 transcripts/g RNA. Twenty-four months after his alloBMT, the patient received a donor lymphocyte infusion (DLI) (1 × 10 7 CD3 + cells/kg). Cytogenetic and molecular evidence of relapse persisted in marrow examined 6 weeks after DLI, and therefore a second course of DLI (5 × 10 7 CD3 + cells/kg) was administered 2 months after the first infusion. Due to continuing evidence of cytogenetic and molecular relapse 6 months after the second DLI, a third course (1 × 10 8 CD3 + cells) was administered. Cytogenetic and molecular remission were confirmed by studies on bone marrow 6 weeks after this infusion. In trephine sections, no granuloma or giant cells were seen. Eighteen months after the third DLI, and 4 years post alloBMT, the patient continues to be in remission from both CML and sarcoidosis.
Discussion
Studies on alloHSCT in immune disorders have suggested that suppression of the auto-reactive clone of cells may be mediated by interactions with donor lymphocytes. 5 These interactions may be analogous to the GVL response seen when DLI are used to re-induce remission in relapsed CML post alloHSCT. However, it may be argued that intensive pretransplant conditioning of alloHSCT rather than GVA attenuates immune dysfunction in immune disorders, by eliminating auto-reactive lymphocytes.
At the time of relapse of CML, our patient was noted to have giant cell granulomata in his marrow, along with increased levels of serum ACE. These pathological features could not be attributed to the presence of co-existing infection, drug reaction or non-haematologic malignancies, and on account of the family history of sarcoidosis, our patient appeared to have developed sarcoidosis concomitantly with CML relapse. This provided an opportunity to study the effects of DLI independent of myeloablative therapy, on the clinical course of sarcoidosis along with CML. The remission of CML following DLI indicates the presence of GVL, the simultaneous resolution of sarcoidosis suggests amelioration of immune mechanisms giving rise to this immune-mediated disorder. It is not possible to comment on whether suppression of sarcoidosis was mediated by activity of donor lymphocytes against clones of cells giving rise to sarcoidosis, or if the GVL effect had enabled activation of mechanisms previously suppressed by CML.
The origin of the cells which induced sarcoidosis, and whose properties were modulated by DLI is unclear. Due to a strong familial predisposition and the presence of HLA-B8, 9 the clones responsible for sarcoidosis could have originated from within our patient once cytoreduction of the dominant CML clone had been achieved. Equally, it is possible that sarcoidosis was transferred from donor to recipient during the alloBMT. 10 Marrow was harvested from the donor when the sarcoidosis was quiescent, and it is possible that the host microenvironment may have facilitated the development of donor pre-thymic precursors or Th subsets into cells that initiated the sarcoid reaction. In addition, the time-period after alloBMT at which sarcoidosis was diagnosed coincides with the time at which CD4 + lymphocyte counts are known to recover in alloBMT recipients 11 and this further suggests that the sarcoidosis may have originated from the donor.
This report raises more questions than answers, but regardless of the origin of sarcoidosis in our patient, the response to DLI suggests that infusion of immunocompetent T lymphocytes may potentially attenuate the mechanisms causing the sarcoid reaction. One could therefore speculate a role for T cell-based immunotherapy in the treatment of sarcoidosis 12 but definitive studies on the pathogenesis of sarcoidosis and mechanisms of DLImediated immunosuppression are required.
